Related Experiment Video
Updated: Mar 15, 2026

07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
3.0K
Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
Norasyikin A Wahab1, Suehazlyn Zainudin1, Aini AbAziz2
1Endocrine Unit, Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Archives of Iranian Medicine
|September 16, 2016
Summary
Advanced adrenal cell carcinoma is aggressive, often diagnosed late. A multi-approach therapy in a young patient with advanced adrenal cancer, including vena cava thrombosis and pulmonary embolism, achieved a survival of over 5 years.
Area of Science:
- Oncology
- Endocrinology
Background:
- Adrenal cell carcinoma (ACC) is a rare, aggressive endocrine tumor with a poor prognosis, frequently diagnosed at advanced stages.
- Current treatment standards include surgical intervention and mitotane, with etoposide, doxorubicin, and cisplatin plus mitotane approved as first-line therapy since 2012.
Observation:
- This case report details an advanced adrenal cell carcinoma in a pediatric patient presenting with a large adrenal mass, inferior vena cava thrombosis, and pulmonary embolism.
- The patient exhibited a large adrenal mass complicated by significant vascular invasion and metastatic disease.
Findings:
- A multi-approach therapeutic strategy was implemented to manage the extensive tumor burden and metastatic spread.
- This comprehensive treatment plan resulted in a prolonged survival of up to 5 years and 4 months for the patient.
Implications:
- This case highlights the potential efficacy of multi-modal therapy in managing advanced and complex adrenal cell carcinoma cases, even in young patients.
- Aggressive, tailored treatment strategies may offer extended survival benefits for patients with advanced adrenal cell carcinoma, challenging the typically poor prognosis.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Metastasis
6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K

